EUVIMEDEUVIMED entdecken
Crossref

Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study

Yosuke Aoyama, Yukinori Ozaki, Rika Kizawa, Jun Masuda, Saori Kawai, Mami Kurata, Tetsuyo Maeda, Kazuyo Yoshida, Nami Yamashita, Meiko Nishimura, Mari Hosonaga, Ippei Fukada und 4 weitere

Breast Cancer · 2025-03 · 32 (2) · 329-336

DOI: 10.1007/s12282-024-01657-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer, online erschienen am 07.12.2024. Verfasst von Yosuke Aoyama und 15 weiteren Autor:innen. Beteiligte Einrichtung: Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Neoadjuvant Therapy, Antineoplastic Combined Chemotherapy Protocols, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsNeoadjuvant TherapyAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedHumansFemaleMiddle AgedErb-b2 Receptor Tyrosine KinasesReceptors, EstrogenRetrospective StudiesAdultAgedJapanFeasibility StudiesNeoplasm StagingCarboplatinTreatment OutcomePaclitaxelEast Asian People

Stichwörter der Autor:innen

ER-low HER2-negative tumorPembrolizumab plus chemotherapyTriple-negative breast cancer

Substanzen

Erb-b2 Receptor Tyrosine KinasesAntibodies, Monoclonal, HumanizedReceptors, EstrogenCarboplatinPaclitaxelpembrolizumabERBB2 protein, human

Autor:innen und Institutionen

  • Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan.
  • Breast Oncology Center, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31, Ariake, Koto, Tokyo, 135-8550, Japan. takayuki.ueno@jfcr.or.jp.

Zitieren

APA

Aoyama, Y., Ozaki, Y., Kizawa, R., Masuda, J., Kawai, S., Kurata, M., Maeda, T., Yoshida, K., Yamashita, N., Nishimura, M., Hosonaga, M., Fukada, I., Hara, F., Kobayashi, T., Takano, T., & Ueno, T. (2025). Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study. Breast Cancer, 32(2), 329-336. https://doi.org/10.1007/s12282-024-01657-4

Vancouver

Aoyama Y, Ozaki Y, Kizawa R, Masuda J, Kawai S, Kurata M, et al. Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study. Breast Cancer. 2025;32(2):329-336. doi:10.1007/s12282-024-01657-4

BibTeX
@article{Aoyama2025,
  author = {Aoyama, Yosuke and Ozaki, Yukinori and Kizawa, Rika and Masuda, Jun and Kawai, Saori and Kurata, Mami and Maeda, Tetsuyo and Yoshida, Kazuyo and Yamashita, Nami and Nishimura, Meiko and Hosonaga, Mari and Fukada, Ippei and Hara, Fumikata and Kobayashi, Takayuki and Takano, Toshimi and Ueno, Takayuki},
  title = {Efficacy and feasibility of neoadjuvant pembrolizumab plus chemotherapy for early-stage triple-negative and estrogen receptor low, HER2-negative breast cancer: a Japanese single-institution real-world study},
  journal = {Breast Cancer},
  year = {2025},
  volume = {32},
  number = {2},
  pages = {329--336},
  doi = {10.1007/s12282-024-01657-4}
}
Kostenlos starten →